Journal of Psychopharmacology

Article	Citations
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	196
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	137
The chronic effects of a combination of herbal extracts (Euphytose®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	125
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	93
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	70
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	57
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	54
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA)	53
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	51
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	51
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression	51
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	50
Award winning abstracts presented at the 15 th Annual International College of Mental Health Pharmacy (CMHP) Conference, Liverpool, UK, on 10	50
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	47
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	46
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	45
Psychedelics and the ‘inner healer’: Myth or mechanism?	45
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	43
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	41
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	41
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	41
The effects of antenatal depression and SSRI exposure on children: A systematic review	40
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	39
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	36
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	36

A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	36
Comparison of average time-to-relapse following ECT versus ketamine – A systematic review	36
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	35
Psychedelic research – Going global	34
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	33
Not too quick on “Debunking the myth of ‘Blue Mondays’”	33
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	32
The therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials	30
Every prescription is a prediction	30
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data	30
Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature	29
Postpartum depression: A role for psychedelics?	28
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust	28
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	28
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	27
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	27
The New Zealand drug harms ranking study: A multi-criteria decision analysis	27
Elevated C-reactive protein among symptomatic youth with bipolar disorder	27
What are set and setting: Reducing vagueness to improve research and clinical practice	27
Psychedelic-assisted psychotherapy: The need to monitor adverse events	26
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs	26
Antipsychotic co-medication and treatment response to rTMS and iTBS in depression: Data from clinical records from two independent clinical sites	26
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19 / CYP2D6 genes play a	25
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	25
Impact of psychedelics on craving in addiction: A systematic review	24
Statistical limitations of the claimed dose–response in “Dose–response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials”	23
The low risk for early renal damage during lithium treatment has not changed over time	23
Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review	23
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α2-adrenoceptor sensitivity	21
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study	21
The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences	21
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	21
The mechanism of action of clozapine	20
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	20
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	20
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	20
Drug–drug interactions involving classic psychedelics: A systematic review	20
Factor analysis of treatment acceptability in double-blind randomised clinical trial of home-based transcranial direct current stimulation in major depression and in healthy individuals	19
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	19
Effect of CannEpil ® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	19
Psilocybin for clinical indications: A scoping review	19
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	19
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR9) measure of suicidal risk	18
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	18
Eight-week antidepressant treatment effects on connectome gradient in first-episode drug-naïve patients with major depressive disorder	18
The antidepressant effect and safety of non-intranasal esketamine: A systematic review	18
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	18
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	18
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	17
The effects of reserpine on depression: A systematic review	17

A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	17
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression	17
Modafinil: A closer look at its theoretical toxicological potential	17
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	17
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	16
Assessment of the reporting of harms in systematic reviews focused on hallucinogens: A cross-sectional study	16
Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial	16
Escitalopram and functional connectivity in major depressive disorder: A systematic review	16
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 5	16
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	15
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	15
Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	15
Negative affect interacts with perceptual affective biases	15
The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database	15
Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin®) in adults experiencing high stress and fatigue in a randomized, double-blin	15
Examining the role of systemic chronic inflammation in diet and sleep relationship	14
Episodic foresight is impaired following acute alcohol intoxication	14
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review	14
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	14
Older adults in psychedelic-assisted therapy trials: A systematic review	14
Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience	13
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	13
Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review	13
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	13
The role of psychopharmacology and cognitive neuroscience in understanding the brain in the treatment of psychiatric disorders and neurological diseases for the benefit of society	13
Subjectively reported sleep improvement with antipsychotic medications in clinical practice: A systematic review, meta-analysis and meta-regression of moderating factors	13
Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications	13
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial	13
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	13
Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis	12
Concomitant use of antidepressants and classic psychedelics: A scoping review	12
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	12
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	12
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	12
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	12
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	12
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	12
The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls	12
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study	12
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	12
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations	11
The psychedelic effects of cannabis: A review of the literature	11
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	11
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	11
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder	11
The psychopharmacology of mood disorders	11
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	11
Common protein networks for various drug regimens of major depression are associated with complement and immunity	11
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	11
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	11
Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	11
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy vo	11
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments	11
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	11
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	11
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	10
Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights	10
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	10
Role of chemokines in depression: Highlights on CX 3 CL1/CX 3 CR1 signaling	10
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	10
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	10
Landscape analysis of pre-registered clinical trials involving classical psychedelics	10
Clinical correlates of early onset antipsychotic treatment resistance	9
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	9
Ketamine: A new chapter for clinical psychopharmacology?	9
Interactions of alcohol and the benzodiazepine inverse agonist in healthy male volunteers	9
Role of serotonin in modulation of decision-making in Parkinson’s disease	9
Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference?	9
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	9
Trip killers: Addressing a critical knowledge gap in psychedelic research	9
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	9
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	9
Mapping acute alcohol effects on bodily sensations: A cross-dimensional interoceptive approach	8
Increasing recreational nitrous oxide use: Should we worry? A narrative review	8
Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model	8
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression	8
Modification of natural tryptamines for the treatment of neuropsychiatric diseases	8
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice	8
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	8
Effect of ashwagandha ( Withania somnifera ) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, pl	8

Role of α1-GABAA receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression	8
Prenatal THC exposure and binge-like alcohol drinking in early adolescence: From sex-specific drinking vulnerability to abnormal endocannabinoid-dopamine nexus in the nucleus accumbens	8
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	8
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis	8
Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics	8
Appraisal of the validity of preclinical investigations to predict the efficacy of psychedelic drugs as fast-acting antidepressants	8
An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice	7
Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports	7
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazol	7
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis	7
Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics	7
Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times	7
Psilocybin history, action and reaction: A narrative clinical review	7
Award winning abstracts presented at the 14th Annual International College of Mental Health Pharmacy (CMHP) Conference Glasgow, UK, on 11th and 12th October 2024	7
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression	7
“Too small to succeed?” Rethinking efficacy claims in a solriamfetol trial for ME/CFS	7
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review	7
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview	7
Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients	7
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers’ task group on psychedelics and related compoun	6
Roles of the 5-HT1A receptor in zebrafish responses to potential threat and in sociality	6
Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder	6
Severe neutropenia unrelated to clozapine in patients receiving clozapine	6
Adolescent substance use trajectories are associated with nucleus accumbens functional connectivity	6
Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose–response model-based network meta-analysis	6
Boosting the ventrolateral periaqueductal gray-ventral tegmental area pathway by disinhibition of group II mGluRs alleviates chronic restraint stress-induced depression-like behavior in mice	6
Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia – a systematic review	6
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction	6
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study	6
Harnessing placebo: Lessons from psychedelic science	6
Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review	6
Characteristics of poisonings involving ketamine in the United States, 2019–2021	6
Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”	6
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study	6
Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis	6
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics	6
Metformin efficacy and safety as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial	6
Influence of GABAA and GABAB receptor activation on auditory sensory gating and its association with anxiety in healthy volunteers	6
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine	6
β -blockers’ neuropsychiatric risks: Overlooked evidence?	6
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase	6
Nucleus accumbens serotonin 1A receptor expression is altered by female reproduction and regulates postpartum affective and caregiving behaviors	6
Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review	5
Associations of treatment with hypnotics with suicide and attempted suicide: A nationwide cohort study	5
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study	5
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder	5
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes	5
CYP1A2 genotype-dependent effects of smoking on mirtazapine serum concentrations	5
The relationship between Parkinson’s disease and sexual hyperactivity secondary to drug treatment: A systematic review	5
Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors	5
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	5
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers	5
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review	5
Individual differences in cocaine-induced conditioned place preference in male rats: Behavioral and transcriptomic evidence	5
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response	5
Impact of childhood adversity on acute subjective effects of stimulant and opioid drugs: Evidence from placebo-controlled studies in healthy volunteers	5
Clinical effects of CYP2D6 phenoconversion in patients with psychosis	5
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure	5
Award winning abstracts presented at the 12th Annual International College of Mental Health Pharmacy (CMHP) Conference, Northampton, UK on 7th and 8th October 2022	5
Effects of gamma-aminobutyric acid on working memory and attention: A randomized, double-blinded, placebo-controlled, crossover trial	5
Impaired face symmetry detection under alcohol, but no ‘beer goggles’ effect	5
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis	5
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats	5
Antipsychotic action and symptom specificity – down the bioinformatic rabbit hole	5
Effects of ketamine enantiomers on morphine and THC subjective effects in rats	5
Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial	5
Oral sodium oxybate does not alter plasma kisspeptin levels in healthy male volunteers	5
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study	5
MDMA enhances positive affective responses to social feedback	5
Habitual caffeine intake, genetics and cognitive performance	5
Association of polygenic risk for cannabis use disorder with brain structure among youth with and without bipolar disorder	4
Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety	4
Predicting clozapine dose required to achieve a therapeutic plasma concentration – A comparison of a population algorithm and three algorithms based on gene variant models	4
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers	4
Antipsychotic medication in people with intellectual disability and schizophrenia: A 25-year updated systematic review and cross-sectional study	4
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment	4
Psychiatric risks for worsened mental health after psychedelic use	4
Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments	4
Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System datab	4
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B r	4
Ketamine for refractory depression: Save the best for last?	4
Individual and combined effects of cannabidiol and Δ9-tetrahydrocannabinol on striato-cortical connectivity in the human brain	4
Effects of electroconvulsive shock on astroglial reactivity in a rat model of antipsychotic-induced neurotoxicity	4
ICPN meeting abstracts	4
Brain serotonin, oxytocin, and their interaction: Relevance for eating disorders	4
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression	4
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics	4
Enhancement of memory network activity in schizophrenia patients by phosphodiesterase-4 (PDE4) inhibitor, roflumilast: A pilot study	4
A meta-analysis of potential genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness	4
The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor	4
Clozapine treatment in adolescents with schizophrenia and autism spectrum disorder: Comparative clinical profiles and treatment outcomes from a retrospective study	4
Towards precision dosing in psychiatry: Population pharmacokinetics meta-modelling of clozapine and lithium	4
Dose of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding in older adults	4
Reward-related neural activity after low doses of LSD in participants with depressed mood	4
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients	4